<DOC>
	<DOCNO>NCT00120393</DOCNO>
	<brief_summary>Patients HIV virologically suppress lopinavir/ritonavir combination highly active antiretroviral therapy ( HAART ) regimen elevate non-HDL cholesterol randomize remain lopinavir/ritonavir change atazanavir/ritonavir combination current nucleoside reverse transcriptase inhibitor ( NRTIs ) .</brief_summary>
	<brief_title>Study HIV Patients With Undetectable Viral Load Abnormal Lipids Switching Atazanavir/Ritonavir</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>HIV positive LPV/RTVbased HAART least 6 month HIV1 RNA le 50c/mL ( confirm ) NonHDL high 160 mg/dL CD4 least 50 cells/mL Use lipidlowering agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>